echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Professor Deng Xianming's research group published a paper in "EMBO Mol Med" to report a new generation of ALK inhibition...

    Professor Deng Xianming's research group published a paper in "EMBO Mol Med" to report a new generation of ALK inhibition...

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 30, 2021, the research group of Professor Deng Xianming from the State Key Laboratory of Cellular Stress Biology, the National and Local Joint Engineering Laboratory for Targeted Drugs from Natural Product Sources, and the School of Life Sciences of Xiamen University jointly published a title in "EMBO Molecular Medicine" For the research paper "A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC" ( http://doi.
    org/10.
    15252/emmm.
    202114296), a new generation of ALK inhibitor XMU-MP- 5.
    It can effectively overcome the clinical drug resistance mutation of non-small cell lung cancer caused by the first and second generation ALK inhibitors
    .


    This study provides a new lead compound for the development of a new generation of ALK-targeted drugs, which is expected to bring new hope to patients with clinical resistance to ALK inhibitors


    The fusion gene EML4-ALK produced by chromosomal rearrangement is one of the important oncogenes in non-small cell lung cancer
    .


    Since the FDA approved Crizotinib as the first-generation small molecule inhibitor of EML4-ALK in 2011, the currently used ALK inhibitors have achieved significant clinical efficacy, but with the prolongation of medication time, patients inevitably develop Resistance mutations to existing drugs


    The paper was completed by our laboratory, the School of Life Science and Technology of Jinan University, the School of Basic Medicine of Peking University, and the National Center for Translational Medicine of Shanghai Jiaotong University.
    Sheng Zhuang Zhongji is responsible for the design, synthesis and optimization of this series of compounds.
    Professor Zhang Jianming, Professor Yunhong, Professor Chen Liang and Professor Deng Xianming are the co-corresponding authors
    .


    The research was funded by the key research and development program of the Ministry of Science and Technology, the National Natural Science Foundation of China, and the basic scientific research business expenses of central universities


    【Professor Deng Xianming's team profile】

    Professor Deng Xianming's team carried out innovative drug discovery research around "novel kinases" targeting pathways and targets related to major diseases
    .


    In the past five years, relevant results have been published in Cell , Sci.


    Original link: http://doi.


    (Photo/Wen Deng Xianming's research group)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.